Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 04, 2019

PF-05280014 + Paclitaxel Is Equivalent to Reference Trastuzumab + Paclitaxel for HER2+ MBC

British Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

British Journal of Cancer
PF-05280014 (a Trastuzumab Biosimilar) Plus Paclitaxel Compared With Reference Trastuzumab Plus Paclitaxel for HER2-Positive Metastatic Breast Cancer: A Randomised, Double-Blind Study
Br. J. Cancer 2018 Dec 20;[EPub Ahead of Print], MD Pegram, I Bondarenko, MMC Zorzetto, S Hingmire, H Iwase, PV Krivorotko, KS Lee, RK Li, J Pikiel, R Aggarwal, R Ewesuedo, A Freyman, R Li, A Vana, D Yin, C Zacharchuk, E Tan-Chiu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading